Freia Farmaceutici grows in Europe thanks to Sativa Hemp
Since ancient times, Hemp has been a plant of infinite opportunities: from the feeding of the Roman legionaries to the Gutenberg Bible, from the rigging of the Maritime Republics to the American Constitution, this wonderful plant has gone through the history of humanity in many forms. The fibers of the plant have been the raw material for the production of textiles and ropes, as well as paper. Then things changed in the early decades of the 1900s, when this plant was the subject of a campaign that associated its image with drugs, thus leading to the abandonment of its industrial cultivation. In the early 2000s, however, a new turnaround occurred. It is estimated that in Italy the sativa hemp market would create at least 10 thousand jobs and a redevelopment of structures that are no longer in use,
Among the most active companies in Europe - and the first to move in Italy - there is the Milanese Freia Farmaceutici, born in 2009 from the idea of the young entrepreneur Alessandro Guido Cavalieri Manasse with the aim of developing innovative medical devices, dietetic foods for special doctors and food supplements based on derivatives of hemp seed sativa. “In this sector - CEO Cavalieri Manasse tells affaritaliani.it - we were pioneers, because talking about hemp in Italy in 2009 was like talking about drugs. The idea was born by comparing myself with some Israeli researchers who had developed a series of products derived from this plant. Hence my interest and my passion ”.
The Milanese company dedicated the first years of activity to the search for new methods for the cultivation of hemp sativa, aimed at the formulation of products useful for human health. In 2014, research and development efforts were accompanied by the commitment to market research in Italy, through medical information activities aimed at ratifying the real value of its solutions and their therapeutic potential. Since its foundation, investment in basic and applied research has been the main driver of its business.
"In 2017 - continues the CEO - we started to reap the benefits of our hard work, with the launch of our products on the national market and registration in the register of innovative SMEs". An important growth path was that of Freia, which culminated in May 2019, with the entry of the Canadian Elixxer fund into the company's capital, an international partnership with high potential, also with a view to a forthcoming expansion in other markets, especially in Europe, North American and Asian.
"We are a full-fledged pharmaceutical company - he continues - and we work in three directions: research and development in the agronomic field, trying to develop new plant varieties of hemp plant, research and development in the extractive field and research and development in the pharmacological field with several clinical trials in collaboration with Italian and foreign universities. Today we are one of the two European companies that have developed therapeutic solutions based on hemp sativa authorized by their respective public health protection bodies, free of THC and CBD. We have seven patents and others in approval and different product lines, marketed since 2017 and registered with the Ministry of Health, useful for human health in the cardiovascular, dermatological, allergological and gynecological fields ".
The Company aims to achieve an important position in dermatological and chronic-degenerative pathologies, through the development of innovative therapeutic solutions easily accessible to patients. The research project which also involves the development of a therapeutic solution for the treatment of multiple sclerosis is very significant.
“Freia has always - based Cavalieri Manasse - bases its products on sativa hemp and extracts the active ingredients from its seeds, free of THC and CBD. We have conducted several clinical trials in the therapeutic areas for which our products are intended, demonstrating their therapeutic efficacy. Our product portfolio currently includes solutions for the treatment of cardiovascular and metabolic diseases, with the aim of developing new therapies for patients with atherosclerosis, dyslipidemia, hypertension and metabolic diseases, including diabetes and its related complications. We are also committed to developing therapeutic solutions for dermatological and dermo-oncological diseases, offering innovative therapies for radiodermatitis, dermatitis and psoriasis ".
The Company's 2020-23 product platform provides for the launch of new solutions in the gynecological, gastroenterological and nutritional fields, as well as the further development of the lines already on the market. All Freia Farmaceutici products are free of THC and CBD, GMOs, gluten and lactose, are vegan and laboratory tested, without using animals.
"The launch on the market of our solutions, which took place in 2017 - concludes Marco Santini, CFO of the Company - allowed Freia to grow by 74% in 2018, when the company posted a sales volume of 856 thousand euros, with an EBITDA margin of 22% ".
For more information: https://www.freiafarmaceutici.it/